Key points from article :
ReWalk Robotics has a new name and a much bigger plan.
The company, now called Lifeward, is trying to grow beyond being known mainly for robotic exoskeletons. Its goal is to build a broader rehabilitation business that can support people through different stages of recovery, from the clinic to everyday life at home.
That shift has been building for several years.
Lifeward’s best-known product is the ReWalk Personal Exoskeleton, a wearable robotic system designed to help some people with neurological conditions stand and walk. The company also offers other rehabilitation technologies, including the ReStore Exo-Suit and MyoCycle systems.
But one of the biggest changes came when the company acquired AlterG for $19 million.
AlterG is known for its anti-gravity treadmills. These machines reduce the amount of body weight a person feels while walking or running. That can make movement easier and less painful during rehabilitation.
The technology is already widely used in rehabilitation clinics and sports settings. For Lifeward, that existing clinic network is important because many people using its products begin their recovery under the supervision of healthcare professionals.
By bringing AlterG into the business, Lifeward gained access to thousands of clinics and rehabilitation centers in the US. It also gave the company a wider range of products to offer patients and therapists.
The idea is fairly simple: rehabilitation is rarely about one device.
Someone recovering from an injury or living with a neurological condition may need different types of support at different stages. A person may start with assisted exercise in a clinic, use equipment that makes walking easier, and later move toward technology that can support greater independence at home.
Lifeward wants to be involved across more of that journey.
Another major development came from Medicare.
Changes made by the Centers for Medicare & Medicaid Services created a clearer reimbursement pathway for certain powered mobility devices, including technologies such as the ReWalk Personal Exoskeleton.
That matters because advanced rehabilitation devices can be expensive. Even if a doctor believes a device could help a patient, access can be difficult when insurance coverage is unclear.
Better reimbursement does not automatically mean every patient will receive an exoskeleton. Eligibility, medical need and individual circumstances still matter. But clearer Medicare coverage could make it easier for some patients to access these technologies and for doctors to consider prescribing them.
For Lifeward, the change could also open a much larger market.
The company has said that patient interest was never the main problem. The bigger challenge was creating a practical route from medical recommendation to payment and real-world access.
That is why the Lifeward rebrand is about more than changing a company name.
It reflects a wider strategy: combine multiple rehabilitation technologies, build stronger relationships with clinics and make those products easier for patients to access.
There are still questions ahead. Rehabilitation technology can be costly, not every device works for every patient and long-term outcomes remain important when deciding whether new technologies provide real value.
Still, the direction is clear.
Lifeward is betting that the future of rehabilitation will not rely on one machine or one moment in a patient’s recovery. Instead, it may involve a connected range of tools that help people move more safely, rebuild strength and gain more independence over time.
For patients, that bigger picture may ultimately matter far more than the company’s new name.
